<?xml version="1.0" encoding="UTF-8"?>
<search_results count="72">
  <query>Victrelis</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT01181804</nct_id>
    <title>Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>177</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P06992</other_id>
    </other_ids>
    <first_received>August 12, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>March 23, 2012</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Concentration Curve (AUC) From Hour 0 to the Final Quantifiable Sample (AUCtf) for Boceprevir Tablets Versus Capsules in Fed State</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Boceprevir Tablets Versus Capsules in Fed State</outcome_measure>
      <outcome_measure>AUCtf for Boceprevir Tablets Versus Capsules in Fasted State</outcome_measure>
      <outcome_measure>Cmax of Boceprevir Tablets Versus Capsules in Fasted State</outcome_measure>
      <outcome_measure>AUC From Hour 0 to Infinity (AUCinf) in Fed State</outcome_measure>
      <outcome_measure>AUCinf in Fasted State</outcome_measure>
      <outcome_measure>Half Life (t1/2) of Boceprevir in Fed State</outcome_measure>
      <outcome_measure>t1/2 Boceprevir in Fasted State</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01181804</url>
  </study>
  <study rank="2">
    <nct_id>NCT01396005</nct_id>
    <title>A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">methadone</intervention>
      <intervention type="Drug">buprenorphine/naloxone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08123</other_id>
    </other_ids>
    <first_received>June 28, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 25, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>December 6, 2012</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Concentration Versus Time Curve (AUC) at Steady State of Methadone Enantiomers When Administered With or Without Boceprevir</outcome_measure>
      <outcome_measure>Maximum Concentration (Cmax) at Steady State of Methadone Enantiomers When Administered With or Without Boceprevir</outcome_measure>
      <outcome_measure>AUC of Buprenorphine (Administered in Combination With Naloxone) at Steady State With or Without Boceprevir</outcome_measure>
      <outcome_measure>Cmax of Buprenorphine (Administered in Combination With Naloxone) at Steady State With or Without Boceprevir</outcome_measure>
      <outcome_measure>AUC of Naloxone (Administered in Combination With Buprenorphine) at Steady State With or Without Boceprevir</outcome_measure>
      <outcome_measure>Cmax of Naloxone (Administered in Combination With Buprenorphine) at Steady State With or Without Boceprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01396005</url>
  </study>
  <study rank="3">
    <nct_id>NCT00959699</nct_id>
    <title>A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to Boceprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05411</other_id>
      <other_id>MK-3034-025</other_id>
    </other_ids>
    <first_received>July 29, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 8, 2013</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24 (FW24) Among Randomized Participants Who Received At Least One Dose of Trial Medication</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Among Randomized Participants Who Received At Least One Dose of Boceprevir (Experimental) or Placebo (Control)</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable HCV-RNA at Follow-up Week 12 (FW12)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 HCV-RNA at Treatment Week 4 (TW4)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV Virologic Breakthrough or Incomplete Virologic Response/Rebound</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00959699</url>
  </study>
  <study rank="4">
    <nct_id>NCT01471717</nct_id>
    <title>Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">INX-08189 50 mg QD X 5 days</intervention>
      <intervention type="Drug">INX-08189 / Victrelis 800 mg TID X three days</intervention>
      <intervention type="Drug">Victrelis 800 mg TID x 3 days</intervention>
      <intervention type="Drug">Victrelis 800 mg TID with INX-08189 50 mg QD</intervention>
      <intervention type="Drug">Placebo with Victrelis 800 mg</intervention>
      <intervention type="Drug">Cohort 2: Victrelis 800 mg with Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-004</other_id>
      <other_id>INX-189-004</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>June 21, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>INX-189-004</acronym>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>PK parameters of INX-08189, INX-08032, and Victrelis when dosed alone and in combination</outcome_measure>
      <outcome_measure>Safety parameters, including adverse event, concurrent medication, clinical laboratory, ECG, PE, and VS assessments</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Minnesota</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01471717</url>
  </study>
  <study rank="5">
    <nct_id>NCT01663922</nct_id>
    <title>Boceprevir and Ucalm (St John&amp;Apos;s Wort)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">St John's Wort</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St Stephens Aids Trust</lead_sponsor>
      <collaborator>University of Liverpool</collaborator>
      <collaborator>University of Turin, Italy</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SSAT 045</other_id>
    </other_ids>
    <first_received>August 3, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>September 23, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>July 14, 2014</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic of Boceprevir in the Presence of Ucalm (St John's Wort)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01663922</url>
  </study>
  <study rank="6">
    <nct_id>NCT00705432</nct_id>
    <title>Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1472</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05216</other_id>
      <other_id>EUDRACT # 2007-005508-42</other_id>
    </other_ids>
    <first_received>June 24, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <acronym>SPRINT-2</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705432</url>
  </study>
  <study rank="7">
    <nct_id>NCT01657552</nct_id>
    <title>Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thrombocytopaenia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltrombopag</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>116010</other_id>
    </other_ids>
    <first_received>August 2, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>May 16, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Composite pharmacokinetic (PK) parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of boceprevir following administration of boceprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of eltrombopag following administration of telaprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of telaprevir following administration of telaprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Composite PK parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag</outcome_measure>
      <outcome_measure>Safety and tolerability as assessed by the collection of adverse events</outcome_measure>
      <outcome_measure>Safety and tolerability as assessed by change from baseline in clinical laboratory tests</outcome_measure>
      <outcome_measure>Safety and tolerability as assessed by change from baseline in vital sign</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01657552</url>
  </study>
  <study rank="8">
    <nct_id>NCT01590225</nct_id>
    <title>Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alpha-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08034</other_id>
      <other_id>2010-024260-17</other_id>
    </other_ids>
    <first_received>May 1, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>August 2021</completion_date>
    <last_updated>February 20, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2021</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants Achieving Sustained Viral Response (SVR) at Follow-Up Week 24 in Study Part A</outcome_measure>
      <outcome_measure>Participants Achieving SVR at Follow-Up Week 24 in Study Part B</outcome_measure>
      <outcome_measure>Time to Viral Relapse in Study Part C</outcome_measure>
      <outcome_measure>Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part A</outcome_measure>
      <outcome_measure>Participants With Early Virologic Response in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part B</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA in Study Part B</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Treatment-Emergent Adverse Events (AEs) in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Treatment-Emergent Treatment-Related AEs in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Serious AEs (SAEs) in Study Part A</outcome_measure>
      <outcome_measure>Participants Discontinuing Treatment Due to AEs in Study Part A</outcome_measure>
      <outcome_measure>Change from Baseline in Participant Laboratory Values in Study Part A</outcome_measure>
      <outcome_measure>Change From Baseline in Participant Vital Signs in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing AEs in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Experiencing SAEs in Study Part B</outcome_measure>
      <outcome_measure>Change from Baseline in Participant Laboratory Values in Study Part B</outcome_measure>
      <outcome_measure>Change From Baseline in Participant Vital Signs in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing From Study Treatment Due to AEs in Study Part B</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01590225</url>
  </study>
  <study rank="9">
    <nct_id>NCT01425190</nct_id>
    <title>Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P07614</other_id>
      <other_id>2010-023498-20</other_id>
      <other_id>MK-3034-063</other_id>
    </other_ids>
    <first_received>August 26, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 3, 2014</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Plasma Concentration Time Curve (AUC) From 0-Infinity of Single Dose Boceprevir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Single Dose Boceprevir</outcome_measure>
      <outcome_measure>Time of Maximum Plasma Concentration (Tmax) of Single Dose Boceprevir</outcome_measure>
      <outcome_measure>Final Dose of Boceprevir By Age Group</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Germany</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01425190</url>
  </study>
  <study rank="10">
    <nct_id>NCT02160080</nct_id>
    <title>Boceprevir Treatment in Liver Pre-transplant HCV Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Late Complication From Liver Transplant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hu Tsung-Hui</lead_sponsor>
      <collaborator>Chang Gung Memorial Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB:102-4331A</other_id>
    </other_ids>
    <first_received>April 11, 2014</first_received>
    <start_date>January 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>June 10, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>HCV-RNA (Hepatitis C virus RNA) level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02160080</url>
  </study>
  <study rank="11">
    <nct_id>NCT01390844</nct_id>
    <title>Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
      <intervention type="Drug">Placebo to boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Cross-Over Boceprevir Treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>282</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P07063</other_id>
      <other_id>2007-005151-42</other_id>
      <other_id>3034-033</other_id>
      <other_id>CTRI/2012/04/002540</other_id>
    </other_ids>
    <first_received>July 7, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 9, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response, defined as undetectable plasma hepatitis C virus ribonucleic acid (HCV-RNA) at Follow-up Week 24 in participants who received at least one dose of any trial medication (i.e. PEG, RBV, BOC, or placebo)</outcome_measure>
      <outcome_measure>Sustained virologic response, defined as undetectable plasma HCV-RNA at Follow-up Week 24 in participants who received at least one dose of experimental trial medication (i.e. placebo or BOC)</outcome_measure>
      <outcome_measure>Number of participants achieving early virologic response (undetectable HCV-RNA at Treatment Week 8)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01390844</url>
  </study>
  <study rank="12">
    <nct_id>NCT02113631</nct_id>
    <title>Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C,</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Louis Stokes VA Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB #: 11064-H40</other_id>
    </other_ids>
    <first_received>March 30, 2014</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/Adverse Event Outcome Measure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02113631</url>
  </study>
  <study rank="13">
    <nct_id>NCT01627717</nct_id>
    <title>The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Maraviroc (5 days)</intervention>
      <intervention type="Drug">Maraviroc and boceprevir (14 days)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centre hospitalier de l'Université de Montréal (CHUM)</lead_sponsor>
      <collaborator>Université de Montréal</collaborator>
      <collaborator>McGill University Health Center</collaborator>
      <collaborator>Toronto General Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MVC.1201</other_id>
    </other_ids>
    <first_received>June 21, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>May 30, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in maraviroc AUC</outcome_measure>
      <outcome_measure>Change in maraviroc Tmax</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Change in maraviroc Cmax</outcome_measure>
      <outcome_measure>Change in maraviroc Cmin</outcome_measure>
      <outcome_measure>Change in maraviroc Cl/F</outcome_measure>
      <outcome_measure>Change in maraviroc Vd</outcome_measure>
      <outcome_measure>Change in maraviroc T1/2</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01627717</url>
  </study>
  <study rank="14">
    <nct_id>NCT00689390</nct_id>
    <title>Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Boceprevir</intervention>
      <intervention type="Biological">Narlaprevir</intervention>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Blood/Plasma Collection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1954</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05063</other_id>
      <other_id>2006-006529-25</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 1, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response)</outcome_measure>
      <outcome_measure>Kaplan-Meier Exposure-adjusted Relapse Rate</outcome_measure>
      <outcome_measure>Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) Reported During the LTFU</outcome_measure>
      <outcome_measure>Number of Participants That Discontinued the LTFU Due to SAEs</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00689390</url>
  </study>
  <study rank="15">
    <nct_id>NCT01499498</nct_id>
    <title>The Boceprevir and Sildenafil Pharmacokinetics Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sildenafil and Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BOC_PK</other_id>
    </other_ids>
    <first_received>November 4, 2011</first_received>
    <start_date>December 2012</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>November 6, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 9, 2014</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sildenafil Alone Maximum Plasma Concentration</outcome_measure>
      <outcome_measure>Boceprevir Alone Maximum Plasma Concentration</outcome_measure>
      <outcome_measure>Sildenafil Maximum Plasma Concentration</outcome_measure>
      <outcome_measure>Boceprevir Maximum Plasma Concentration</outcome_measure>
      <outcome_measure>Number of Patients With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01499498</url>
  </study>
  <study rank="16">
    <nct_id>NCT01457937</nct_id>
    <title>Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Menopause</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon, Ribavirin, Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Modena and Reggio Emilia</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EudraCT 2011-002459-33</other_id>
    </other_ids>
    <first_received>October 8, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 29, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MEN_BOC</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement of sustained virological response in previous treatment failure or naive HCV-positive menopausal women.</outcome_measure>
      <outcome_measure>Early virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01457937</url>
  </study>
  <study rank="17">
    <nct_id>NCT01288417</nct_id>
    <title>Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>HCV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">raltegravir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCN-AKF 10.05</other_id>
    </other_ids>
    <first_received>January 26, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>July 23, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>OPAL</acronym>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>raltegravir concentrations</outcome_measure>
      <outcome_measure>adverse events</outcome_measure>
      <outcome_measure>boceprevir concentrations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01288417</url>
  </study>
  <study rank="18">
    <nct_id>NCT01463956</nct_id>
    <title>Clinical Trial to Evaluate the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
      <condition>Liver Cirrhosis, Experimental</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peg-Interferon α-2b or Peg-Interferon α-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011- 001089 -17</other_id>
    </other_ids>
    <first_received>October 14, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>January 14, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Perceived symptoms</outcome_measure>
      <outcome_measure>Compliance rate.</outcome_measure>
      <outcome_measure>SVR prognosis factors</outcome_measure>
      <outcome_measure>The predictive value of on-treatment HCV RNA on SVR</outcome_measure>
      <outcome_measure>The percentage of virologic failure</outcome_measure>
      <outcome_measure>The percentage of relapse after transplantation</outcome_measure>
      <outcome_measure>Boceprevir resistant mutations</outcome_measure>
      <outcome_measure>Resistant mutations in plasma and liver samples (both explanted liver and graft)</outcome_measure>
      <outcome_measure>Sepsis according to Systemic Inflammatory Response System (SIRS) Criteria</outcome_measure>
      <outcome_measure>Cirrhosis impairment</outcome_measure>
      <outcome_measure>Survival after transplantation</outcome_measure>
      <outcome_measure>Survival rate within one year after liver transplantation</outcome_measure>
      <outcome_measure>The mean time elapsed between registration on the transplantation list and the date of transplantation</outcome_measure>
      <outcome_measure>Measurement of the residual plasma concentration (Cres) of ribavirin</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration Time Curve (AUC) From 0-8h of Boceprevir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Boceprevir</outcome_measure>
      <outcome_measure>Time of Maximum Plasma Concentration (Tmax) of Boceprevir</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Boceprevir</outcome_measure>
      <outcome_measure>Correlation study between the presence of an elevated level of IP-10 during triple therapy and the absence of sustained virologic response</outcome_measure>
      <outcome_measure>Histological severity of HCV recurrence after liver transplantation</outcome_measure>
      <outcome_measure>Insulin Resistance (HOMA-IR)</outcome_measure>
      <outcome_measure>Virological Response in participants with and without Insulin Resistance</outcome_measure>
      <outcome_measure>Relationship between the presence of a polymorphism in the IL28B gene (donor and recipient) and SVR</outcome_measure>
      <outcome_measure>Relationship between the presence of a polymorphism to the ITPA gene and the onset of hemolytic anemia</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01463956</url>
  </study>
  <study rank="19">
    <nct_id>NCT00845065</nct_id>
    <title>Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05685</other_id>
    </other_ids>
    <first_received>February 13, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 10, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population.</outcome_measure>
      <outcome_measure>SVR Rate in the Modified Intent-to-Treat (mITT) Population</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12</outcome_measure>
      <outcome_measure>Mean Log Change From Baseline to TW 4 in Viral Load by Visit</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00845065</url>
  </study>
  <study rank="20">
    <nct_id>NCT00160251</nct_id>
    <title>Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
      <intervention type="Biological">PegIntron (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>357</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03659</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Sustained Viral Response (SVR) by Time to First Negative HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were HCV-RNA Negative at EoT After Receiving 1 Week of Treatment With PegIntron (PEG) by Log Drop</outcome_measure>
      <outcome_measure>Percent of Participants With Virologic Response Prior to Amendment 2</outcome_measure>
      <outcome_measure>Peak Plasma Concentration of Boceprevir (BOC)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve of Boceprevir Plasma Concentration for an 8-hour Dosing Period</outcome_measure>
      <outcome_measure>Trough Plasma Concentration Level</outcome_measure>
      <outcome_measure>Change in Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on Arms 2 (PEG+BOC 100), 3 (PEG+BOC 200), 4 (PEG+BOC 400 [48 Weeks]), 6 (PEG+BOC 400 [24 Weeks])</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Rebetol (RVB) + Boceprevir (BOC) 400 (Arm 5)</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Boceprevir (BOC) 800 (Arm 7)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00160251</url>
  </study>
  <study rank="21">
    <nct_id>NCT00423670</nct_id>
    <title>Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir (SCH 503034)</intervention>
      <intervention type="Drug">peginterferon-alfa 2b (PegIntron)</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin (low-dose)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>765</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03523</other_id>
      <other_id>EudraCT No. 2006-002543-92</other_id>
    </other_ids>
    <first_received>January 17, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>February 16, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With SVR Based on a 4-week lead-in Treatment With PegIntron and Ribavirin</outcome_measure>
      <outcome_measure>Number of Participants With SVR Based on Duration of Boceprevir Treatment</outcome_measure>
      <outcome_measure>Number of Participants Negative for HCV-RNA at FW 12</outcome_measure>
      <outcome_measure>Number of Participants Negative for HCV-RNA at 72 Weeks Post Randomization</outcome_measure>
      <outcome_measure>Number of Participants With an Early Virologic Response (EVR) That Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With a Virologic Response at Follow-up Week 12 That Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With a Virologic Response at 72 Weeks Post Randomization That Achieved SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00423670</url>
  </study>
  <study rank="22">
    <nct_id>NCT02112630</nct_id>
    <title>Boceprevir in End Stage Renal Disease (ESRD)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">P-IFN alfa 2a</intervention>
      <intervention type="Drug">P-IFN alfa 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AAAL5200</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>May 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients who achieve sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02112630</url>
  </study>
  <study rank="23">
    <nct_id>NCT00708500</nct_id>
    <title>Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (SCH 503034)</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
      <intervention type="Drug">Boceprevir placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>404</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05101</other_id>
      <other_id>2007-005151-42</other_id>
    </other_ids>
    <first_received>June 27, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population.</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response.</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00708500</url>
  </study>
  <study rank="24">
    <nct_id>NCT01427504</nct_id>
    <title>Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir; etravirine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-1046</other_id>
    </other_ids>
    <first_received>August 24, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>June 4, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>November 16, 2012</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Boceprevir AUC Pharmacokinetics</outcome_measure>
      <outcome_measure>Boceprevir Cmax Pharmacokinetics</outcome_measure>
      <outcome_measure>Boceprevir C8 Pharmacokinetics</outcome_measure>
      <outcome_measure>Etravirine AUC Pharmacokinetics</outcome_measure>
      <outcome_measure>Etravirine Cmax Pharmacokinetics</outcome_measure>
      <outcome_measure>Etravirine Cmin Pharmacokinetics</outcome_measure>
      <outcome_measure>Boceprevir AUC Pharmacokinetics Coadministered With Etravirine</outcome_measure>
      <outcome_measure>Boceprevir Cmax Pharmacokinetics Coadministered With Etravirine</outcome_measure>
      <outcome_measure>Boceprevir C8 Pharmacokinetics Coadministered With Etravirine</outcome_measure>
      <outcome_measure>Etravirine AUC Pharmacokinetics Coadministered With Boceprevir</outcome_measure>
      <outcome_measure>Etravirine Cmax Pharmacokinetics Coadministered With Boceprevir</outcome_measure>
      <outcome_measure>Etravirine Cmin Pharmacokinetics Coadministered With Boceprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01427504</url>
  </study>
  <study rank="25">
    <nct_id>NCT01731301</nct_id>
    <title>A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Liver Institute of Virginia</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Chronic Liver Disease Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIV01</other_id>
    </other_ids>
    <first_received>November 16, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>November 20, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients who achieve eRVR at treatment week 28</outcome_measure>
      <outcome_measure>Tolerability of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01731301</url>
  </study>
  <study rank="26">
    <nct_id>NCT01585584</nct_id>
    <title>Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Calgary</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MISP #39897</other_id>
      <other_id>24411</other_id>
    </other_ids>
    <first_received>April 18, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>August 22, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 22, 2015</firstreceived_results_date>
    <acronym>LeeG3</acronym>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) at 24 Weeks Post Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01585584</url>
  </study>
  <study rank="27">
    <nct_id>NCT01641666</nct_id>
    <title>Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b 1.5 mcg/kg/week</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08599</other_id>
    </other_ids>
    <first_received>July 11, 2012</first_received>
    <start_date>May 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 7, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing a Serious Adverse Event (SAE) During the Study Therapy Period</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641666</url>
  </study>
  <study rank="28">
    <nct_id>NCT01544582</nct_id>
    <title>Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>719</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08518</other_id>
      <other_id>EP08043.001</other_id>
      <other_id>SCH 503034 P08518</other_id>
    </other_ids>
    <first_received>February 2, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>June 30, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Boceprevir utilization versus other therapies</outcome_measure>
      <outcome_measure>Clinical management of health outcomes of interest ([HOI], anemia, neutropenia, thrombocytopenia, or serious rash)</outcome_measure>
      <outcome_measure>Incidence of anemia, neutropenia, thrombocytopenia, and serious skin rash</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01544582</url>
  </study>
  <study rank="29">
    <nct_id>NCT01597895</nct_id>
    <title>Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Maraviroc</intervention>
      <intervention type="Drug">Maraviroc + Boceprevir</intervention>
      <intervention type="Drug">Maraviroc + Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ViiV Healthcare</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A4001108</other_id>
    </other_ids>
    <first_received>May 10, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 18, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maraviroc plasma pharmacokinetic parameters: AUC12, Cmax, and C12h on Period 1, Day 5 and Periods 2 and 3, Day 10</outcome_measure>
      <outcome_measure>Maraviroc plasma pharmacokinetic parameters: Tmax on Period 1, Day 5 and Periods 2 and 3, Day 10</outcome_measure>
      <outcome_measure>Boceprevir plasma pharmacokinetic parameters: AUC8, Cmax, C8h, and Tmax on Period 2, Day 10</outcome_measure>
      <outcome_measure>Telaprevir plasma pharmacokinetic parameters: AUC8, Cmax, C8h, and Tmax on Period 3, Day 10</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01597895</url>
  </study>
  <study rank="30">
    <nct_id>NCT01949168</nct_id>
    <title>A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)</intervention>
      <intervention type="Drug">Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection</intervention>
      <intervention type="Drug">Rebetol® (ribavirin), 1000/1200mg by mouth daily</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St Vincent's Hospital Melbourne</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme (Australia) Pty Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-6 study</other_id>
    </other_ids>
    <first_received>September 4, 2013</first_received>
    <start_date>September 2013</start_date>
    <last_updated>September 19, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCV-6</acronym>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early viral kinetics</outcome_measure>
      <outcome_measure>Rates of virological response</outcome_measure>
      <outcome_measure>Number of patients eligible for Response Guided Therapy</outcome_measure>
      <outcome_measure>Rates of virological breakthrough</outcome_measure>
      <outcome_measure>Rates of SVR12 and relapse</outcome_measure>
      <outcome_measure>Rates of anaemia on treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01949168</url>
  </study>
  <study rank="31">
    <nct_id>NCT01925183</nct_id>
    <title>Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Markus Peck-Radosavljevic</lead_sponsor>
      <collaborator>Medical University of Vienna</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HIVCOBOC-RGT</other_id>
      <other_id>2012-005591-33</other_id>
    </other_ids>
    <first_received>August 15, 2013</first_received>
    <start_date>August 2013</start_date>
    <last_updated>August 16, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HIVCOBOC-RGT</acronym>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Adverse events (AEs) and severe adverse events (SAEs)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Anemia</outcome_measure>
      <outcome_measure>Thrombocytopenia</outcome_measure>
      <outcome_measure>Neutropenia</outcome_measure>
      <outcome_measure>Erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) analogues use</outcome_measure>
      <outcome_measure>Treatment discontinuation due to AEs</outcome_measure>
      <outcome_measure>Drop-outs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01925183</url>
  </study>
  <study rank="32">
    <nct_id>NCT01756079</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-105</other_id>
      <other_id>2012-002772-13</other_id>
    </other_ids>
    <first_received>December 19, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 29, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who achieve sustained viral response (SVR) at 24 weeks after the end of all study treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01756079</url>
  </study>
  <study rank="33">
    <nct_id>NCT00910624</nct_id>
    <title>Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05514</other_id>
    </other_ids>
    <first_received>May 28, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>September 18, 2013</firstreceived_results_date>
    <acronym>PROVIDE</acronym>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24);</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) Leading to Dose Modification (DM) or Discontinuation (DC), Treatment-Related Serious AEs (SAEs), Neutrophil Count &lt;0.75 × 10^9/L, or Hemoglobin (Hgb) &lt;10 g/dL</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00910624</url>
  </study>
  <study rank="34">
    <nct_id>NCT01023035</nct_id>
    <title>Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (PEG2b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Erythropoietin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>687</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P06086</other_id>
      <other_id>2009-012782-63</other_id>
    </other_ids>
    <first_received>November 24, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 16, 2012</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01023035</url>
  </study>
  <study rank="35">
    <nct_id>NCT01544920</nct_id>
    <title>Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>737</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P07755</other_id>
      <other_id>2011-001345-32</other_id>
      <other_id>MK-3034-040</other_id>
      <other_id>CTRI/2012/12/003200</other_id>
      <other_id>PHRR131022-000133</other_id>
    </other_ids>
    <first_received>February 28, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 18, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall Number of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR at Follow-up Week 24 Among Those Participants Who Had Achieved Rapid Virologic Response (RVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01544920</url>
  </study>
  <study rank="36">
    <nct_id>NCT01425203</nct_id>
    <title>The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>238</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08160</other_id>
      <other_id>MK-3034-046</other_id>
    </other_ids>
    <first_received>August 26, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 29, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication (Full Analysis Set Population)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Among Participants Who Received At Least One Dose of Experimental Trial Drug (Modified Intent-To-Treat [mITT] Population)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Early Virologic Response (EVR) At Treatment Week (TW) 8</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01425203</url>
  </study>
  <study rank="37">
    <nct_id>NCT01470690</nct_id>
    <title>Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infections</condition>
      <condition>Gastric Acid-related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">Omeprazole</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCN-AKF 10.06</other_id>
    </other_ids>
    <first_received>November 1, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>November 26, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PROMO</acronym>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>boceprevir concentrations</outcome_measure>
      <outcome_measure>omeprazole concentrations</outcome_measure>
      <outcome_measure>adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01470690</url>
  </study>
  <study rank="38">
    <nct_id>NCT02060058</nct_id>
    <title>Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Stop trial intervention for boceprevir, PEG-IFN and RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
      <collaborator>National Taiwan University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUHIRB-2013-10-03 (I)</other_id>
    </other_ids>
    <first_received>January 27, 2014</first_received>
    <start_date>November 2013</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>February 9, 2014</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BOLERO-CB</acronym>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary endpoint of this clinical trial-SVR and FAS for HCV RNA</outcome_measure>
      <outcome_measure>Key secondary endpoint of this clinical trial-SVR in mITT and HBV DNA surge</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02060058</url>
  </study>
  <study rank="39">
    <nct_id>NCT01335529</nct_id>
    <title>Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Coinfection</condition>
      <condition>HIV-1 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir, Peg-interferon alfa 2b and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Rennes University Hospital</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC27 BOCEPREVIH</other_id>
    </other_ids>
    <first_received>March 25, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>October 10, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BocepreVIH</acronym>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Predictive factors of Sustained virologic Response (SVR)</outcome_measure>
      <outcome_measure>HIV virologic endpoints</outcome_measure>
      <outcome_measure>Residual plasmatic concentration (Cres) of Ribavirin</outcome_measure>
      <outcome_measure>Hepatic factors: liver fibrosis score</outcome_measure>
      <outcome_measure>Alcohol consumption</outcome_measure>
      <outcome_measure>Evaluation of Pharmacokinetic parameters of anti-retroviral treatments</outcome_measure>
      <outcome_measure>Clinical and biological adverse events</outcome_measure>
      <outcome_measure>Number of participants classified by virologic failure type: non responder, relapser, null responder</outcome_measure>
      <outcome_measure>ITPA gene polymorphism</outcome_measure>
      <outcome_measure>CYP3A4 Polymorphism</outcome_measure>
      <outcome_measure>Maximal Concentration (Cmax) of antiretroviral treatments</outcome_measure>
      <outcome_measure>Area Under the Curve (AUC) of antiretrovirals</outcome_measure>
      <outcome_measure>Insulin resistance</outcome_measure>
      <outcome_measure>Metabolic syndrome</outcome_measure>
      <outcome_measure>Reasons and dates of treatment discontinuation</outcome_measure>
      <outcome_measure>Perceived symptoms</outcome_measure>
      <outcome_measure>French AIDS questionnaire of compliance</outcome_measure>
      <outcome_measure>Tobacco consumption</outcome_measure>
      <outcome_measure>Cannabis consumption</outcome_measure>
      <outcome_measure>Intravenous/nasal drugs consumption</outcome_measure>
      <outcome_measure>Residual Concentration (Cres) of atazanavir boosted or not by ritonavir</outcome_measure>
      <outcome_measure>Residual concentration (Cres) of ritonavir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01335529</url>
  </study>
  <study rank="40">
    <nct_id>NCT01446250</nct_id>
    <title>Study of DEB025/Alisporivir Plus Pegylated Interferon alfa2a and Ribavirin and Boceprevir Plus Pegylated Interferon alfa2a and Ribavirin in African American Chronic Hepatitis C Genotype 1 Patients That Have Never Received Treatment for Their Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 plus peg-IFN alpha 2a and ribavirin fixed duration treatment</intervention>
      <intervention type="Drug">DEB025 plus peg-IFN alpha 2a and ribavirin response guided treatment duration</intervention>
      <intervention type="Drug">Boceprevir plus peg-IFN alpha 2a and ribavirin per label response guided treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2307</other_id>
    </other_ids>
    <first_received>September 26, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>October 12, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients that discontinue study drug or require dose reduction or dose interruption due to treatment-emergent Adverse Events.</outcome_measure>
      <outcome_measure>Proportion of patients with emergence of resistant mutations in each treatment arm.</outcome_measure>
      <outcome_measure>Proportion of patients that achieve Sustained Viral Response Week 24 (SVR24) defined as serum HCV RNA undetectable by limit of detection (LOD) 24 weeks after end of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01446250</url>
  </study>
  <study rank="41">
    <nct_id>NCT01909401</nct_id>
    <title>Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1301010500</other_id>
    </other_ids>
    <first_received>June 13, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 23, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of individuals who can remain HCV RNA undetected 6 months post orthotopic liver transplant after receiving peginterferon, ribavirin, and boceprevir.</outcome_measure>
      <outcome_measure>Safety and efficacy of peginterferon, ribavirin, and boceprevir in patients with genotype I undergoing orthotopic liver transplant for cirrhosis and/or hepatocellular carcinoma.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Indiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01909401</url>
  </study>
  <study rank="42">
    <nct_id>NCT01912495</nct_id>
    <title>Dutch Acute HCV in HIV Study (DAHHS)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Erasmus Medical Center</lead_sponsor>
      <collaborator>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</collaborator>
      <collaborator>Onze Lieve Vrouwe Gasthuis</collaborator>
      <collaborator>UMC Utrecht</collaborator>
      <collaborator>University Medical Center Groningen</collaborator>
      <collaborator>Maastricht University Medical Center</collaborator>
      <collaborator>Rijnstate Hospital</collaborator>
      <collaborator>Slotervaart Hospital</collaborator>
      <collaborator>Radboud University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL44825.078.13</other_id>
    </other_ids>
    <first_received>July 29, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DAHHS</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Responds(SVR) 12 weeks of follow up after the end of all therapy for the Rapid Viral Response at week 4(RVR4) population.</outcome_measure>
      <outcome_measure>SVR 12 weeks after the end of all therapy in the entire study population (with or without RVR4).</outcome_measure>
      <outcome_measure>SVR 12 weeks after end of therapy in patients with already a RVR at week 1.</outcome_measure>
      <outcome_measure>SVR 12 weeks after end of therapy in patients that started therapy ≤12weeks after the presumed HCV infection date versus those after 12 weeks.</outcome_measure>
      <outcome_measure>Alterations of biomarkers by therapy induced viral eradication: Viral sequencing, mutation analysis, gene expression analysis, and RNA analysis.</outcome_measure>
      <outcome_measure>Safety: Treatment related (serious) adverse events ((S)AE) and treatment discontinuation for (S)AE.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01912495</url>
  </study>
  <study rank="43">
    <nct_id>NCT01591460</nct_id>
    <title>A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin (Copegus]</intervention>
      <intervention type="Drug">ribavirin (Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV28073</other_id>
      <other_id>2011-004810-41</other_id>
    </other_ids>
    <first_received>May 2, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>July 10, 2015</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 24 Weeks After EOT</outcome_measure>
      <outcome_measure>HCV RNA Levels</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response</outcome_measure>
      <outcome_measure>Percentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Relapse Following EOT Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Breakthrough Following On-Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA</outcome_measure>
      <outcome_measure>Duration of Treatment With PEG-IFN, RBV, and Boceprevir</outcome_measure>
      <outcome_measure>Percentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason</outcome_measure>
      <outcome_measure>Percentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir</outcome_measure>
      <outcome_measure>Number of Participants With a Safety-Related Dose Modification</outcome_measure>
      <outcome_measure>Time to Safety-Related Dose Modification</outcome_measure>
      <outcome_measure>Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up</outcome_measure>
      <outcome_measure>Percentage of Participants With a Concomitant Disease Prior to or During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Using Concomitant Medications During Treatment and Follow-Up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01591460</url>
  </study>
  <study rank="44">
    <nct_id>NCT01403181</nct_id>
    <title>Effect of Boceprevir on HCV-specific T Cell Responses</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliero-Universitaria di Parma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AZOSPA</other_id>
    </other_ids>
    <first_received>July 26, 2011</first_received>
    <start_date>April 2012</start_date>
    <last_updated>November 5, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Boce-Par</acronym>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Levels of HCV-specific T cell functions before, during and after therapy to measure functional restoration induced by therapy</outcome_measure>
      <outcome_measure>Correlation of quality and intensity of pre-treatment HCV-specific T cell responses with outcome of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01403181</url>
  </study>
  <study rank="45">
    <nct_id>NCT01770223</nct_id>
    <title>A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-113</other_id>
      <other_id>2012-002771-33</other_id>
    </other_ids>
    <first_received>January 15, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with sustained virologic response (SVR) at 24 weeks after the end of 48 weeks of study treatment</outcome_measure>
      <outcome_measure>Change from baseline in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01770223</url>
  </study>
  <study rank="46">
    <nct_id>NCT01482403</nct_id>
    <title>A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">mericitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV27780</other_id>
      <other_id>2011-002714-37</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virological response 4 weeks after treatment</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Proportion of patients who develop treatment resistance</outcome_measure>
      <outcome_measure>Safety (incidence of adverse events)</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO4995855</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO5012433</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of boceprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482403</url>
  </study>
  <study rank="47">
    <nct_id>NCT01465516</nct_id>
    <title>Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Regional Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>38950</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>June 27, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR based on intention to treat analysis</outcome_measure>
      <outcome_measure>Tolerance</outcome_measure>
      <outcome_measure>BDI II score 31 or above</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01465516</url>
  </study>
  <study rank="48">
    <nct_id>NCT01549496</nct_id>
    <title>A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amlodipine</intervention>
      <intervention type="Drug">Diltiazem</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ottawa Hospital Research Institute</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>OHRI-BCP-CCB-2012</other_id>
    </other_ids>
    <first_received>March 1, 2012</first_received>
    <start_date>May 2012</start_date>
    <last_updated>January 7, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>pharmacokinetics</outcome_measure>
      <outcome_measure>number of participants with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01549496</url>
  </study>
  <study rank="49">
    <nct_id>NCT01405027</nct_id>
    <title>Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Educational Intervention</intervention>
      <intervention type="Other">Patient education and management skills training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chronic Liver Disease Foundation</lead_sponsor>
      <collaborator>SCRI Development Innovations, LLC</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLDF-MER-001-00</other_id>
      <other_id>20111013</other_id>
    </other_ids>
    <first_received>July 25, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>December 22, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>November 17, 2014</firstreceived_results_date>
    <acronym>OPTIMAL</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment Duration Compliance Rate</outcome_measure>
      <outcome_measure>Drug Exposure</outcome_measure>
      <outcome_measure>Determination of the Rate of Sustained Viral Response (SVR) for HCV Patients Treated With Boceprevir, Peginterferon and Ribavirin at Community Sites and at HCEEs.</outcome_measure>
      <outcome_measure>Short Form Health Survey Measuring Quality of Life Reported at Baseline, End of Treatment, and Follow-up Week 24 (36 Multiple Choice Questions)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01405027</url>
  </study>
  <study rank="50">
    <nct_id>NCT01718301</nct_id>
    <title>HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
      <condition>COINFECTION</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Anna Cruceta</lead_sponsor>
      <collaborator>Fundacion Clinic per a la Recerca Biomédica</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BOC-HIV</other_id>
      <other_id>2012-003984-23</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BOC-HIV</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Achievement of sustained virological response (SVR) at week 24</outcome_measure>
      <outcome_measure>Achievement of sustained virological response at weeks 2,4,8,12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at FW 12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at 72 weeks after randomization.</outcome_measure>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Resistance of HCV after boceprevir (BOC) containing regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01718301</url>
  </study>
  <study rank="51">
    <nct_id>NCT01653236</nct_id>
    <title>Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Genotype 4 Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Theodor Bilharz Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-108</other_id>
    </other_ids>
    <first_received>July 26, 2012</first_received>
    <start_date>December 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 25, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Week 8 Response</outcome_measure>
      <outcome_measure>12 Weeks response</outcome_measure>
      <outcome_measure>IL-28B polymorphism</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01653236</url>
  </study>
  <study rank="52">
    <nct_id>NCT02204475</nct_id>
    <title>Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir/Elbasvir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-066</other_id>
      <other_id>2014-001841-25</other_id>
    </other_ids>
    <first_received>July 28, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving SVR12</outcome_measure>
      <outcome_measure>Proportion of TN participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants withdrawing from study treatment due to AEs</outcome_measure>
      <outcome_measure>Proportion of PTF participants achieving SVR12</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02204475</url>
  </study>
  <study rank="53">
    <nct_id>NCT01353911</nct_id>
    <title>Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Placebo for Grazoprevir</intervention>
      <intervention type="Drug">Placebo for Boceprevir</intervention>
      <intervention type="Drug">Peg-interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>368</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-003</other_id>
    </other_ids>
    <first_received>May 12, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving complete Early Viral Response (cEVR) in the Grazoprevir Treatment Arms</outcome_measure>
      <outcome_measure>Number of participants experiencing adverse events</outcome_measure>
      <outcome_measure>Number of participants discontinued from study due to adverse events</outcome_measure>
      <outcome_measure>Number of Participants Achieving Sustained Viral Response 24 weeks After the End of All Study Therapy (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01353911</url>
  </study>
  <study rank="54">
    <nct_id>NCT01443923</nct_id>
    <title>Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>HIV/AIDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peg-Interferon-alfa 2B</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>110253</other_id>
      <other_id>11-I-0253</other_id>
    </other_ids>
    <first_received>September 29, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>July 9, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>February 25, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy, Defined as Sustained Viral Response (SVR) Six Months After the End of Specified Treatment.</outcome_measure>
      <outcome_measure>Change in Early HCV Viral Load Kinetics Between Mono and Co-infected Subjects</outcome_measure>
      <outcome_measure>Safety and Treatment Outcome Measures Stratified by ESA Use</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Are Receiving HAART Who Remain With an HIV RNA &amp; lt; 400 Copies/mL and Those With HIV RNA &amp; gt; 400 Copies/mL at End of Treatment</outcome_measure>
      <outcome_measure>Efficacy (SVR) Rates as Predicted by Viral Response at the End of the 4-week lead-in Therapy With PEG/RBV and Comparison Between HCV Monoinfected and HIV/HCV Coinfected Subjects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01443923</url>
  </study>
  <study rank="55">
    <nct_id>NCT01482767</nct_id>
    <title>Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-Interferon Alfa 2b (PEG-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>262</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5294 (BIRTH)</other_id>
      <other_id>11774</other_id>
      <other_id>ACTG 5294</other_id>
      <other_id>BIRTH</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>April 2012</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR) defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Grade 3 or higher signs and symptoms and laboratory abnormalities and other serious adverse events (AEs) during the study</outcome_measure>
      <outcome_measure>Undetectable HCV RNA discontinuation (SVR12)</outcome_measure>
      <outcome_measure>Baseline HIV-1 viral load and changes from baseline at each post-entry visit</outcome_measure>
      <outcome_measure>Baseline CD4+ T-cell count and changes from baseline at each post-entry visit</outcome_measure>
      <outcome_measure>Baseline fibrosis stage, race, gender, insulin sensitivity, and HCV viral load level</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Grade 2 or higher signs and symptoms and laboratory abnormalities and other serious AEs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482767</url>
  </study>
  <study rank="56">
    <nct_id>NCT01945294</nct_id>
    <title>Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peg-interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>236</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-107</other_id>
    </other_ids>
    <first_received>September 13, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Undetectable HCV RNA at TW 8 Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR12 By Virologic Response At End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Neutrophil Count &lt;0.75 x10^9/L</outcome_measure>
      <outcome_measure>Percentage of Participants With Hemoglobin (Hgb) &lt;10 g/dL</outcome_measure>
      <outcome_measure>Percentage of Participants With Dose Discontinuation/Modification Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Percentage of Participants With Treatment-Related Serious AEs (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01945294</url>
  </study>
  <study rank="57">
    <nct_id>NCT01563328</nct_id>
    <title>A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection, Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DTG</intervention>
      <intervention type="Drug">BCV</intervention>
      <intervention type="Drug">TVR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ViiV Healthcare</lead_sponsor>
      <collaborator>Shionogi</collaborator>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>115697</other_id>
    </other_ids>
    <first_received>March 22, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 31, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Plasma steady-state DTG PK parameters AUC(0-τ), Cmax, Cmin, and Cτ</outcome_measure>
      <outcome_measure>Safety and tolerability parameters as assessed by change from baseline in vital signs n(BP and HR), number of subjects with adverse events and toxicity grading of clinical laboratory tests.</outcome_measure>
      <outcome_measure>Plasma steady-state DTG tmax and t1/2</outcome_measure>
      <outcome_measure>Plasma steady-state TVR and BCV AUC(0-t), Cmax, Cmin, and Ct</outcome_measure>
      <outcome_measure>Plasma steady-state TVR and BCV tmax and t1/2</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01563328</url>
  </study>
  <study rank="58">
    <nct_id>NCT01514890</nct_id>
    <title>French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>675</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS CO20</other_id>
      <other_id>2010-A01273-36</other_id>
    </other_ids>
    <first_received>January 18, 2012</first_received>
    <start_date>February 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 26, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CUPIC</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virological response (SVR) defined by an undetectable RNA by real-time PCR.</outcome_measure>
      <outcome_measure>Virological response during and after the treatment with determination of HCV RNA levels as prevised by the French Early Access Program for the use of protease inhibitors and after the approval.</outcome_measure>
      <outcome_measure>early viral kinetic</outcome_measure>
      <outcome_measure>Rate of premature discontinuation of protease inhibitor, RBV and/or PEG-IFN</outcome_measure>
      <outcome_measure>occurrence of resistant mutants in partial responders (detectable RNA) or after the occurrence of virological breakthrough and long term evolution of these mutations (on serum bank)</outcome_measure>
      <outcome_measure>Evolution of quality of life scores</outcome_measure>
      <outcome_measure>Evaluation of therapeutic observance with auto-questionnaires</outcome_measure>
      <outcome_measure>Rate of adaptation of dosage of protease inhibitors, RBV and/or PEG-IFN</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01514890</url>
  </study>
  <study rank="59">
    <nct_id>NCT01949077</nct_id>
    <title>Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-2124</other_id>
    </other_ids>
    <first_received>September 10, 2013</first_received>
    <start_date>December 2011</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 10, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Level (ng/mL) of serum chemokines.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01949077</url>
  </study>
  <study rank="60">
    <nct_id>NCT02118597</nct_id>
    <title>An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Pegasys and Ribivarin in the Re-Treatment of Chronic Hepatitis C Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML29278</other_id>
    </other_ids>
    <first_received>April 16, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 24 (SVR24), defined as percentage of patients with HCV RNA &lt; 15 IU/mL after the 24-week follow-up</outcome_measure>
      <outcome_measure>Virological response (HCV RNA &lt; 15 IU/mL)</outcome_measure>
      <outcome_measure>Virological breakthrough, defined as either HCV RNA &gt;/= 15 IU/mL in patients with prior virological response or as an increase in RCV RNA &gt;/= 1 log10 above nadir</outcome_measure>
      <outcome_measure>Virological relapse defined as HCV RNA &gt;/= 15 IU/mL during the treatment free follow-up period in patients with virological response at the end of treatment</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation due to futility, defined as: HCV RNA drop &lt; 3 log10 at Week 8, HCV RNA &gt;/= 100 IU/mL at Week 12, or HCV RNA &gt;/= 15 IU/mL at Week 24</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Predictive value of patient demographics</outcome_measure>
      <outcome_measure>Predictive value of liver fibrosis</outcome_measure>
      <outcome_measure>Predictive value of HCV disease characteristics</outcome_measure>
      <outcome_measure>Predictive value of previous virological response (null-response, partial response, or relapse)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02118597</url>
  </study>
  <study rank="61">
    <nct_id>NCT02004379</nct_id>
    <title>Register of Telaprevir and Boceprevir in Routine Clinical Practice</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Fundación Pública Andaluza Progreso y Salud</lead_sponsor>
      <collaborator>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1553</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>FPS-TEL-2013-01</other_id>
    </other_ids>
    <first_received>November 20, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 14, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effectiveness of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated</outcome_measure>
      <outcome_measure>Safety of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02004379</url>
  </study>
  <study rank="62">
    <nct_id>NCT02057003</nct_id>
    <title>Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAA against HCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>Hospital Universitario Reina Sofia</collaborator>
      <collaborator>Hospital Universitario Virgen de la Victoria</collaborator>
      <collaborator>Hospital Universitario de la Princesa</collaborator>
      <collaborator>Hospitales Universitarios Virgen del Rocío</collaborator>
      <collaborator>Hospital Universitario Carlos Haya</collaborator>
      <collaborator>Hospital Torrecárdenas</collaborator>
      <collaborator>Complejo Hospitalario Universitario de Huelva</collaborator>
      <collaborator>Hospital Puerta del Mar</collaborator>
      <collaborator>Hospital Universitario Virgen Macarena</collaborator>
      <collaborator>Hospital de La Línea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR-DAA</other_id>
    </other_ids>
    <first_received>January 6, 2014</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieve SVR to DAA-based therapy as measure of efficacy</outcome_measure>
      <outcome_measure>Number of patients who develop severe adverse events as measure of safety</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to a BOC-based regimen as compared to numbers of patients who achieve SVR to a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who reach undetectable HCV-RNA at week 4 of PI-based therapy as a measure of on-treatment response to therapy.</outcome_measure>
      <outcome_measure>Number of patients who develop adverse events during a BOC-based regimen as compared to numbers of patients who develop adverse events during a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to an interferon-free regimen.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057003</url>
  </study>
  <study rank="63">
    <nct_id>NCT01821625</nct_id>
    <title>Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thrombocytopenia</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltrombopag</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Texas Southwestern Medical Center</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>STU 032013-020</other_id>
    </other_ids>
    <first_received>March 23, 2013</first_received>
    <start_date>April 2013</start_date>
    <last_updated>August 15, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SQUELCH-C</acronym>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of study patients completing antiviral therapy, as per boceprevir prescribing guidelines.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01821625</url>
  </study>
  <study rank="64">
    <nct_id>NCT02333292</nct_id>
    <title>Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">SMV</intervention>
      <intervention type="Drug">DCV</intervention>
      <intervention type="Drug">LED</intervention>
      <intervention type="Drug">PTV/OTV</intervention>
      <intervention type="Drug">DBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GEHEP-MONO</other_id>
    </other_ids>
    <first_received>December 15, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FPSMON201401</acronym>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Patients with Sustained Virological Response</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>Identification of predictors of SVR</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients that receive methadone maintenance therapy</outcome_measure>
      <outcome_measure>Analyze efficacy and safety according to previous treatment outcome</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients with cirrhosis</outcome_measure>
      <outcome_measure>Evaluate impact of SVR on biological, elastographical and clinical parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02333292</url>
  </study>
  <study rank="65">
    <nct_id>NCT02070107</nct_id>
    <title>Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">On Plan</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Louisville</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>OICN130565</other_id>
    </other_ids>
    <first_received>February 19, 2014</first_received>
    <start_date>April 2014</start_date>
    <last_updated>February 20, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment Completion</outcome_measure>
      <outcome_measure>Virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Kentucky</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02070107</url>
  </study>
  <study rank="66">
    <nct_id>NCT01359644</nct_id>
    <title>Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PSI-7977</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Pharmasset</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-040</other_id>
    </other_ids>
    <first_received>May 23, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough During the Treatment Period</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Viral Relapse During Follow-up Period</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Follow-up Week 24</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs) and Grade 3-4 Adverse Events (AEs), During the Treatment Period Prior to Addition of Rescue Therapy</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs), Grade 3-4 Adverse Events (AEs), and Grade 3-4 Abnormalities on Laboratory Test Results During Follow-up Period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01359644</url>
  </study>
  <study rank="67">
    <nct_id>NCT01771653</nct_id>
    <title>Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Southern Illinois University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>KOI-SIUSOM-12-002</other_id>
    </other_ids>
    <first_received>January 16, 2013</first_received>
    <start_date>September 2011</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>August 5, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virologic Response</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Effect of baseline variables on treatment outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01771653</url>
  </study>
  <study rank="68">
    <nct_id>NCT01604291</nct_id>
    <title>An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
      <collaborator>Clalit Health Services</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>959</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28268</other_id>
    </other_ids>
    <first_received>May 21, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)-24 rate: Percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks post completion of treatment</outcome_measure>
      <outcome_measure>Dual versus triple Pegasys-based therapy: SVR-24 rates</outcome_measure>
      <outcome_measure>Correlation between SVR-24 and clinical/demographic baseline values</outcome_measure>
      <outcome_measure>Predictive value of on-treatment factors (RVR, eRVR, EVR, EOT) on virological response (HCV-RNA &lt;50 IU/mL): Percentage of patients with rapid/rapid extended/early/end of treatment response</outcome_measure>
      <outcome_measure>Treatment duration</outcome_measure>
      <outcome_measure>Dose reductions/treatment discontinuations</outcome_measure>
      <outcome_measure>Correlation between dose reductions/treatment interruptions and sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Rate of treatment-induced anemia (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Treatment regimens for HCV treatment induced anemia in routine clinical practice</outcome_measure>
      <outcome_measure>Rate of virological relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01604291</url>
  </study>
  <study rank="69">
    <nct_id>NCT02124044</nct_id>
    <title>Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir and Dalatasvir</intervention>
      <intervention type="Drug">Daclatasvir and Asunaprevir, with or without BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>140065</other_id>
      <other_id>14-CC-0065</other_id>
    </other_ids>
    <first_received>April 25, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The incidence of grade 3 and 4 adverse events (AEs) followingtreatment with DCV/ASV or DCV/ASV/BMS-791325 in HIV-HCV coinfected subjects</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR12</outcome_measure>
      <outcome_measure>Log change in HCV response</outcome_measure>
      <outcome_measure>The association between HIV Viral load &amp; lt; 40 copies/mL but detectable vs. undetectable while on therapy and HIV virologic failure or HIV VL blips.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02124044</url>
  </study>
  <study rank="70">
    <nct_id>NCT02247440</nct_id>
    <title>HCV-HIV Co-infected Patient Cohort in Thailand</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon + ribavirin under HIV physician supervision</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institut de Recherche pour le Developpement</lead_sponsor>
      <collaborator>Ministry of Health, Thailand</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PHPT-HCV</other_id>
    </other_ids>
    <first_received>September 9, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>May 24, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 6 months after treatment discontinuation</outcome_measure>
      <outcome_measure>Safety of treatment</outcome_measure>
      <outcome_measure>Impact of HCV treatment on HIV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02247440</url>
  </study>
  <study rank="71">
    <nct_id>NCT01816490</nct_id>
    <title>THISTLE - The HIV-HCV Silibinin Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intravenous Silibinin (iSIL)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>THISTLE</other_id>
    </other_ids>
    <first_received>March 8, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>THISTLE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency of adverse events during iSIL treatment.</outcome_measure>
      <outcome_measure>Kinetics of the decline in HCV-RNA after 2 weeks of iSIL treatment (difference in IU/ml from day 1 to day 15).</outcome_measure>
      <outcome_measure>Drug levels of iSIL and its influence on the drug-level of co-administrated ART.</outcome_measure>
      <outcome_measure>Proportion of patients with HIV virological failure, i.e. confirmed viremia &gt;50cp/ml.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01816490</url>
  </study>
  <study rank="72">
    <nct_id>NCT01945008</nct_id>
    <title>Observational Study in HCV Chronic Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Istituto Superiore di Sanità</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PITER 01</other_id>
    </other_ids>
    <first_received>September 13, 2013</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2021</completion_date>
    <last_updated>March 24, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) in treated patients</outcome_measure>
      <outcome_measure>Occurrence of severe adverse events and side effects correlated to treatment</outcome_measure>
      <outcome_measure>Quality of life and adherence to treatment</outcome_measure>
      <outcome_measure>Evolution of the possible comorbidities ( HIV and/or HBV coinfections)</outcome_measure>
      <outcome_measure>Occurrence of antiviral resistances</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01945008</url>
  </study>
</search_results>
